Dementia Overview - Concepedia

Principles

Definition

Dementia is a multifaceted research field and academic concept dedicated to the study of cognitive decline and its underlying causes, primarily neurodegenerative processes. This area investigates the mechanisms, diagnosis, progression, and impact of conditions leading to impairments in memory, thinking, and behavior, aiming to develop effective prevention and treatment strategies.

Ontological type

Etiology

Treatment Strategies

Diagnostic Criteria

Key developments

Key Figures

Cholinergic Neurochemical Paradigm era

Mahlon R. DeLong[1] was a prominent neurologist at Johns Hopkins University[3] during this era. His 1982 paper 'Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain'[6] highlighted basal forebrain neuron loss and cholinergic disruption, shaping brain–behavior models and early therapeutic strategies within the cholinergic paradigm. Bengt Winblad[2] is associated with Umeå University[4] and the University of Gothenburg[5] during this era. His 1979 paper 'Changes in the Brain Catecholamines in Patients with Dementia of Alzheimer Type'[7] documented catecholamine alterations, underscoring catecholaminergic involvement and strengthening the neurochemical framework that linked biochemical changes to clinical syndromes in this era.

Pathology-Centered Diagnostic Framework era

John C. Morris [1], with affiliations at University of Pennsylvania [3] and Washington University in St. Louis [4], was a leading figure in pathology-centered diagnostic standardization during the era. Morris [1] contributed to the development of the Clinical Dementia Rating (CDR) [7], the distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease [8], and the concept of Very Mild Alzheimer's Disease [9], which together established reproducible clinicopathological endpoints and underpinned pathology-first risk stratification in this era. Jeffrey L. Cummings [2], with affiliations at West Los Angeles College [5] and Albert Einstein College of Medicine [6], contributed to vascular dementia within the pathology-centered framework of the era. Cummings [2] authored the 1993 paper Vascular dementia [10], which underscored the role of vascular pathology in cognitive impairment and highlighted the need for standardized, cross-etiology diagnostic criteria in this era.

Biomarker-Driven Dementia Paradigm era

María C. Carrillo [1] is a leading dementia researcher whose work in this era involved Johns Hopkins University [3] and University of California, San Diego [4]. Her contributions, including the recommendations for diagnosing dementia due to Alzheimer's disease [7], Toward defining the preclinical stages of Alzheimer's disease [8], and the National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease [9], anchored a biomarker-informed framework that underpins the era's precision staging and trial design. Clifford R. Jack [2] is a prominent figure associated with the University Memory and Aging Center [5] and Harvard University [6] during this era. His contributions, as reflected in the guideline papers [7] and [8], helped propel the biomarker-driven precision dementia paradigm by clarifying staging from preclinical to clinical Alzheimer's disease and highlighting the role of multimodal biomarkers in diagnosis and trial enrollment.